Lupin Manufacturing Solutions Unveils Dedicated Oncology Block At Vizag, India

• Expanding Global CDMO Capabilities
• New facility strengthens High Potent API development and manufacturing for Oncology Products

Lupin Manufacturing Solutions (LMS), a wholly owned subsidiary of global pharma major Lupin Limited (Lupin), today announced the commissioning of its dedicated Oncology Block at its Vizag facility in India. The new high-containment unit significantly enhances LMS’s end-to-end Contract Development and Manufacturing capabilities for High Potent Active Pharmaceutical Ingredients. It will support clients across the oncology development lifecycle from preclinical research to commercial manufacturing, addressing growing global demand for oncology drug development and manufacturing.

Spanning 4,270 square meters, the new facility, is equipped with 20 reactors, ranging from 250L to 2000L, with over 20 isolators and advanced containment systems, ensuring exposure levels of ≤0.05 µg/m³. Designed with flexible scale-up capabilities (1–35 kg batch range) and comprehensive environmental controls (≤25°C, ≤45% RH), the facility allows for safe, efficient, and compliant production of oncology APIs that meet global quality standards.

Dr. Abdelaziz Toumi, Chief Executive Officer, Lupin Manufacturing Solutions, commented,
“The inauguration of our Oncology Block in Vizag exemplifies our commitment to advancing oncology research and manufacturing. This state-of-the-art facility enhances our capacity to produce high-quality APIs and develop impactful therapies that benefit patients globally. This marks a major milestone in LMS’s evolution into a dedicated and trusted CDMO partner for oncology innovators. With a focus on containment excellence, scalable solutions tailored to each phase, and scientific rigor, this investment enables our global clients to deliver life-changing oncology treatments to patients more quickly, while upholding the highest safety and compliance standards.”

The new facility integrates the Process Development Laboratory with a dedicated Quality Control laboratory, enabling early-stage route scouting, analytical development, process optimization, and validation—all in one location. Supported by scientists with specialized HPAPI expertise, it guarantees seamless transition from lab-scale synthesis to full-scale commercial manufacturing. The facility features advanced containment infrastructure, with isolator-based operations at every process step, integrated SCADA systems, and a robust effluent detoxification system that complies with global regulatory standards, while also adhering to Lupin’s stringent quality and environmental safety protocols.

With this expansion, LMS strengthens its role as a trusted global CDMO partner for oncology innovators. By integrating Lupin’s scientific legacy with advanced containment facilities and regulatory excellence, LMS provides a cohesive ecosystem that supports quicker, safer, and more efficient development of oncology treatments from concept to commercialization, helping clients worldwide to deliver hope to patients.

About Lupin Manufacturing Solutions Limited (LMS)
Lupin Manufacturing Solutions Limited, a 100% subsidiary of Lupin Limited, is a leading manufacturer of active pharmaceutical ingredients (APIs) and a global contract development and manufacturing organization (CDMO) offering standalone & integrated solutions across drug substances, complex chemistry, drug product, and advanced modalities, including ADCs and peptides. Leveraging Lupin’s legacy of scientific rigor and regulatory expertise, LMS supports biopharma innovators from early development to commercial scale. With state-of-the-art facilities, a client-first approach, and a team of 250+ scientists, LMS accelerates the path to market for transformative therapies. For more information, visit https://www.lupin.com/LMS/.

About Lupin
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 24,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions. For more information, visit www.lupin.com.